Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Regulus Therapeutics (RGLS)

Regulus Therapeutics (RGLS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 102,782
  • Shares Outstanding, K 65,466
  • Annual Sales, $ 0 K
  • Annual Income, $ -30,040 K
  • EBIT $ -38 M
  • EBITDA $ -37 M
  • 60-Month Beta 1.62
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.01

Options Overview Details

View History
  • Implied Volatility 103.41% ( -111.29%)
  • Historical Volatility 70.84%
  • IV Percentile 29%
  • IV Rank 7.48%
  • IV High 1,062.00% on 01/22/24
  • IV Low 25.89% on 06/14/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 59
  • Volume Avg (30-Day) 48
  • Put/Call OI Ratio 0.33
  • Today's Open Interest 2,584
  • Open Int (30-Day) 2,284

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate -0.18
  • Number of Estimates 3
  • High Estimate -0.18
  • Low Estimate -0.19
  • Prior Year -0.40
  • Growth Rate Est. (year over year) +55.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.4200 +10.56%
on 10/10/24
1.8480 -15.04%
on 09/23/24
-0.0500 (-3.09%)
since 09/18/24
3-Month
1.3800 +13.77%
on 09/06/24
1.9400 -19.07%
on 07/30/24
-0.1100 (-6.55%)
since 07/18/24
52-Week
1.0800 +45.37%
on 01/17/24
3.7900 -58.58%
on 03/12/24
+0.2800 (+21.71%)
since 10/18/23

Most Recent Stories

More News
Regulus: Q2 Earnings Snapshot

Regulus: Q2 Earnings Snapshot

RGLS : 1.5700 (+3.29%)
Regulus: Q1 Earnings Snapshot

Regulus: Q1 Earnings Snapshot

RGLS : 1.5700 (+3.29%)
Regulus: Q4 Earnings Snapshot

Regulus: Q4 Earnings Snapshot

RGLS : 1.5700 (+3.29%)
Regulus: Q3 Earnings Snapshot

Regulus: Q3 Earnings Snapshot

RGLS : 1.5700 (+3.29%)
Regulus Therapeutics Advances to Cohort 3 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

/PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines...

RGLS : 1.5700 (+3.29%)
Regulus Therapeutics Announces Positive Topline Data from the First Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

/PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines...

RGLS : 1.5700 (+3.29%)
Regulus Therapeutics Announces Completion of Enrollment in Second Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

/PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines...

RGLS : 1.5700 (+3.29%)
Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences

/PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines...

RGLS : 1.5700 (+3.29%)
Regulus: Q2 Earnings Snapshot

Regulus: Q2 Earnings Snapshot

RGLS : 1.5700 (+3.29%)
Regulus Therapeutics Reports Second Quarter 2023 Financial Results and Recent Updates

/PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines...

RGLS : 1.5700 (+3.29%)

Business Summary

Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs, called microRNA therapeutics. The Company's products aim to treat or prevent hepatitis C infections, cardiovascular disease, fibrosis, oncology, immuno-inflammatory diseases, and...

See More

Key Turning Points

3rd Resistance Point 1.7450
2nd Resistance Point 1.6900
1st Resistance Point 1.6300
Last Price 1.5700
1st Support Level 1.5150
2nd Support Level 1.4600
3rd Support Level 1.4000

See More

52-Week High 3.7900
Fibonacci 61.8% 2.7548
Fibonacci 50% 2.4350
Fibonacci 38.2% 2.1152
Last Price 1.5700
52-Week Low 1.0800

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar